Divergence of immunologic and protective responses of different BCG strains in a murine model

Vaccine

Volumn 29, Issue 7, 2011, Pages 1519-1526

  Kozak, R ^a   Behr, M A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

BCG; Immunity; Protection; Tuberculosis

Indexed keywords

BCG VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; GROWTH INHIBITION; IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; LUNG TUBERCULOSIS; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BCG VACCINE; GENETIC COMPLEMENTATION TEST; LUNG; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MUTATION; MYCOBACTERIUM BOVIS; SPLEEN; T-LYMPHOCYTES; TUBERCULOSIS, PULMONARY;

EID: 79151476827     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.012     Document Type: Article

References (50)

1. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006, 367(April 9517):1173-1180.
2. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000, 31(September (Suppl. 3)):S64-S67.
3. Alexander D.C., Behr M.A. Rv1773 is a transcriptional repressor deleted from BCG-Pasteur. Tuberculosis (Edinb) 2007, 87(September 5):421-425.
4. Charlet D., Mostowy S., Alexander D., Sit L., Wiker H.G., Behr M.A. Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK. Mol Microbiol 2005, 56(June 5):1302-1313.
5. Belley A., Alexander D., Di Pietrantonio T., Girard M., Jones J., Schurr E., et al. Impact of methoxymycolic acid production by Mycobacterium bovis BCG vaccines. Infect Immun 2004, 72(May 5):2803-2809.
6. Chen J.M., Alexander D.C., Behr M.A., Liu J. Mycobacterium bovis BCG vaccines exhibit defects in alanine and serine catabolism. Infect Immun 2003, 71(February 2):708-716.
7. Leung A.S., Tran V., Wu Z., Yu X., Alexander D.C., Gao G.F., et al. Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genomics 2008, 9:413.
8. Chen J.M., Islam S.T., Ren H., Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine 2007, 25(November 48):8114-8122.
9. Mostowy S., Tsolaki A.G., Small P.M., Behr M.A. The in vitro evolution of BCG vaccines. Vaccine 2003, 21(October 27-30):4270-4274.
10. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999, 284(May 5419):1520-1523.
11. Lotte A., Wasz-Hockert O., Poisson N., Dumitrescu N., Verron M., Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 1984, 21:107-193.
12. Ulstrup J.C., Jeansson S., Wiker H.G., Harboe M. Relationship of secretion pattern and MPB70 homology with osteoblast-specific factor 2 to osteitis following Mycobacterium bovis BCG vaccination. Infect Immun 1995, 63(February 2):672-675.
13. Lagranderie M.R., Balazuc A.M., Deriaud E., Leclerc C.D., Gheorghiu M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 1996, 64(January 1):1-9.
14. Irwin S.M., Goodyear A., Keyser A., Christensen R., Troudt J.M., Taylor J.L., et al. Immune response induced by three Mycobacterium bovis BCG substrains with diverse regions of deletion in a C57BL/6 mouse model. Clin Vaccine Immunol 2008, 15(May 5):750-756.
15. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Commonly administered BCG strains including an evolutionarily early strain and evolutionarily late strains of disparate genealogy induce comparable protective immunity against tuberculosis. Vaccine 2009, 27(January 3):441-445.
16. Veyrier F., Said-Salim B., Behr M.A. Evolution of the mycobacterial SigK regulon. J Bacteriol 2008, 190(March 6):1891-1899.
17. Divangahi M., Mostowy S., Coulombe F., Kozak R., Guillot L., Veyrier F., et al. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J Immunol 2008, 181(November 10):7157-7165.
18. Reed M.B., Domenech P., Manca C., Su H., Barczak A.K., Kreiswirth B.N., et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 2004, 431(September 7004):84-87.
19. Harboe M., Nagai S., Patarroyo M.E., Torres M.L., Ramirez C., Cruz N. Properties of proteins MPB64, MPB70, and MPB80 of Mycobacterium bovis BCG. Infect Immun 1986, 52(April 1):293-302.
20. Roche P.W., Feng C.G., Britton W.J. Human T-cell epitopes on the Mycobacterium tuberculosis secreted protein MPT64. Scand J Immunol 1996, 43(June 6):662-670.
21. Lagranderie M., Murray A., Gicquel B., Leclerc C., Gheorghiu M. Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine 1993, 11(October 13):1283-1290.
22. Chackerian A.A., Alt J.M., Perera T.V., Dascher C.C., Behar S.M. Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 2002, 70(August 8):4501-4509.
23. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178(Decemer 6):2243-2247.
24. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993, 178(December 6):2249-2254.
25. Sada-Ovalle I., Chiba A., Gonzales A., Brenner M.B., Behar S.M. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog 2008, 4(December 12):e1000239.
26. Parra M., Yang A.L., Lim J., Kolibab K., Derrick S., Cadieux N., et al. Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin Vaccine Immunol 2009, 16(7):1025-1032.
27. Behr M.A., Small P.M. Has BCG attenuated to impotence?. Nature 1997, 389(September 6647):133-134.
28. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007, 104(March 13):5596-5601.
29. Hayashi D., Takii T., Fujiwara N., Fujita Y., Yano I., Yamamoto S., et al. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol Med Microbiol 2009, [April 24].
30. Luo Y., Wang B., Hu L., Yu H., Da Z., Jiang W., et al. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Vaccine 2009, 27(October 44):6179-6185.
31. Qie Y.Q., Wang J.L., Liu W., Shen H., Chen J.Z., Zhu B.D., et al. More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8. 4. Scand J Immunol 2009, 69(April 4):342-350.
32. Sali M., Di Sante G., Cascioferro A., Zumbo A., Nicolo C., Dona V., et al. Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect Immun 2010, 78(December 12):5202-5213.
33. Oettinger T., Holm A., Mtoni I.M., Andersen A.B., Hasloov K. Mapping of the delayed-type hypersensitivity-inducing epitope of secreted protein MPT64 from Mycobacterium tuberculosis. Infect Immun 1995, 63(December 12):4613-4618.
34. Elhay M.J., Oettinger T., Andersen P. Delayed-type hypersensitivity responses to ESAT-6 and MPT64 from Mycobacterium tuberculosis in the guinea pig. Infect Immun 1998, 66(July 7):3454-3456.
35. Silva V.M., Sardella I.G., Luiz R.R., Cunha A.J., Cavalcanti A.H., Mahavir S., et al. Immunoreactivity of five antigens of Mycobacterium tuberculosis in patients attending a public health care facility in an area with high endemicity for TB. Microbiol Immunol 2008, 52(November 11):544-550.
36. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8(April 4):369-377.
37. Sergejeva S., Ivanov S., Lotvall J., Linden A. Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation. Am J Respir Cell Mol Biol 2005, 33(September 3):248-253.
38. Flesch I., Kaufmann S.H. Mycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol 1987, 138(June 12):4408-4413.
39. Walch M., Rampini S.K., Stoeckli I., Latinovic-Golic S., Dumrese C., Sundstrom H., et al. Involvement of CD252 (CD134L) and IL-2 in the expression of cytotoxic proteins in bacterial- or viral-activated human T cells. J Immunol 2009, 182(June 12):7569-7579.
40. Wong P., Pamer E.G. Disparate in vitro and in vivo requirements for IL-2 during antigen-independent CD8 T cell expansion. J Immunol 2004, 172(February 4):2171-2176.
41. Sun R., Skeiky Y.A., Izzo A., Dheenadhayalan V., Imam Z., Penn E., et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 2009, 27(July 33):4412-4423.
42. Comstock G.W. Does the protective effect of neonatal BCG vaccination correlate with vaccine-induced tuberculin reactions?. Am J Respir Crit Care Med 1996, 154(July 1):263-264.
43. Mittrucker H.W., Steinhoff U., Kohler A., Krause M., Lazar D., Mex P., et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci USA 2007, 104(July 30):12434-12439.
44. Castillo-Rodal A.I., Castanon-Arreola M., Hernandez-Pando R., Calva J.J., Sada-Diaz E., Lopez-Vidal Y. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun 2006, 74(March 3):1718-1724.
45. Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003, 71(April 4):1672-1679.
46. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97(December 25):13853-13858.
47. Freund J., Bonanto M.V. The effect of paraffin oil lanolin-like substances and killed tubercle bacilli on immunization with diphtheric toxoid and Bact. Typhosum. J Immunol 1944, 48(5):325-334.
48. Coulombe F., Divangahi M., Veyrier F., de Leseleuc L., Gleason J.L., Yang Y., et al. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med 2009, 206(August 8):1709-1716.
49. Ishikawa E., Ishikawa T., Morita Y.S., Toyonaga K., Yamada H., Takeuchi O., et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 2009, 206(December 13):2879-2888.
50. Maeda N., Nigou J., Herrmann J.L., Jackson M., Amara A., Lagrange P.H., et al. The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan. J Biol Chem 2003, 278(February 8):5513-5516.